ImmunityBio reports $113 million revenue, 700% annual increase
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
January 15, 2026 8:30 AM ESTANKTIVA® sales momentum continues to trend upward with full year preliminary net product revenue of approximately $113.0 million, a ~700% increase year over year The three-month period ending December 31, 2025, preliminary net product revenue of approximately $38.3 million, surpassing net product revenue of $31.8 million in the prior quarter, a 20% quarter over quarter increase and a 431% increase over the three-month period ended December 31, 2024 ANKTIVA Unit Growth: 750% unit sales volume growth in 2025 compared to 2024 Approval Updates: The Saudi FDA (SFDA) granted approval of ANKTIVA® in combination with immune checkpoint inhibitors for adults with metastatic non-small cell lung cancer... More
